Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest PharmaTechQPTFF EV-to-EBIT is 1.03 as of Aug. 13, 2026. Among 367 Biotechnology companies, Quest PharmaTech ranks better than 78.47% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Quest PharmaTech's Enterprise Value for the quarter that ended in Jan. 2026 was $2.97 Mil.
Quest PharmaTech's EBIT for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest PharmaTech EV-to-EBIT Related Terms
Quest PharmaTech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Quest PharmaTech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Quest PharmaTech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest PharmaTech EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Quest PharmaTech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Quest PharmaTech's EV-to-EBIT falls into.
Quest PharmaTech's current Enterprise Value is $3.74 Mil.
Quest PharmaTech's EBIT for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest PharmaTech (QPTFF) has a EV-to-EBIT of 1.03 as of Aug. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Quest PharmaTech and its competitors. According to the industry distribution chart, Quest PharmaTech ranks #79 out of 367 companies in the Biotechnology industry, placing it in the top 21.5%.
Is Quest PharmaTech's EV-to-EBIT too high?
Quest PharmaTech's current EV-to-EBIT is 1.03. The Biotechnology industry median EV-to-EBIT is 15.42. Quest PharmaTech's value of 1.03 is 93.3% below this industry median. Based on the distribution chart, Quest PharmaTech ranks #79 out of 367 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Quest PharmaTech's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Quest PharmaTech ranks #79 out of 367 companies for EV-to-EBIT. This places Quest PharmaTech in the top 22% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.42. Quest PharmaTech's value of 1.03 is 93.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.42, based on 367 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest PharmaTech's current EV-to-EBIT of 1.03 is 93.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Quest PharmaTech and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest PharmaTech's current EV-to-EBIT is 1.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest PharmaTech stock overvalued right now?
Quest PharmaTech (QPTFF) has a current EV-to-EBIT of 1.03. The current EV-to-EBIT is 1.03 and 93.3% below the Biotechnology industry median of 15.42. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Quest PharmaTech (QPTFF), the current EV-to-EBIT is 1.03 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quest PharmaTech Inc is developing targeted cancer therapy with its product (MAb AR9.6), under development for a novel target (truncated O-glycans on MUC16) discovered at the University of Nebraska Medical Center.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
QPTFF has been successfully added to your 
